September 7 2010 - Advinus Therapeutics, the research-based pharmaceutical company promoted by the TATA Group has discovered a novel molecule for the treatment of type II diabetes - GKM -001. The molecule is an activator of glucokinase; an enzyme that regulates glucose balance and insulin secretion in the body.GKM-001 is the completely indigenously developed molecule and the initial clinical trials have shown excellent results for both safety and efficacy.
"Considering past failures of other companies on this target, our discovery program primarily focused on identifying a molecule that would be efficacious without causing hypoglycemia. The Phase I data indicate that GKM - 001 is a liver selective molecule that has overcome the biggest clinical challenge of hypoglycemia. GKM-001 is differentiated from most other GK molecules in development due to this novel mechanism of action... Advinus Therapeutics' Press Release -
